OnKure Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- OnKure Therapeutics Inc.
- Former names
- Reneo Pharmaceuticals, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boulder
- Headquarters state / province
- Colorado
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- OKUR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001637715
- EIN
- 47-2309515
Board of directors
-
Andrew John Phillips · DirectorSince 2024
-
Bali Muralidhar · DirectorSince 2023
- Since 2023
-
Eric M. Dube · DirectorSince 2023
-
Isaac Manke · DirectorSince 2024
-
Liam Ratcliffe · DirectorSince 2026
-
Michael G. Grey · DirectorSince 2023
-
Niall O'Donnell · DirectorSince 2023
-
Nicholas A. Saccomano · Director · President and CEOSince 2024
-
Paul W. Hoelscher · DirectorSince 2023
-
R. Michael Carruthers · DirectorSince 2024
-
Roshawn A. Blunt · DirectorSince 2023
-
Stacey Denenberg Seltzer · DirectorSince 2023
-
Valerie Malyvanh Jansen · DirectorSince 2024
Chief executives
Nicholas A. Saccomano
· President and CEO
Dates unknown
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.3%
-
99.3%
-
99.7%
Board connections
9 of this board's directors also sit on 16 other boards.
- via Bali Muralidhar, Michael G. Grey and Niall O'Donnell
- via Isaac Manke
- via Liam Ratcliffe
- via Liam Ratcliffe
- via Andrew John Phillips
- via Edward T. Mathers
- via Michael G. Grey
- via Andrew John Phillips
- via Isaac Manke
- via Isaac Manke
- via Edward T. Mathers
- via Paul W. Hoelscher
- via Edward T. Mathers
- via Eric M. Dube
- via Edward T. Mathers
- via Liam Ratcliffe
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $5,634
- 8 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −302 | $2.97 | $898 |
| Sep 21, 2026 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −87 | $2.97 | $259 |
| Jun 22, 2026 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −86 | $4.40 | $378 |
| Jun 22, 2026 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −303 | $4.40 | $1,333 |
| Mar 23, 2026 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −86 | $4.16 | $358 |
| Mar 23, 2026 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −301 | $4.16 | $1,252 |
| Dec 31, 2025 | Edward T. Mathers Director | Grant or award | +3,911 | — | — |
| Dec 31, 2025 | Isaac Manke Director | Grant or award | +5,258 | — | — |
| Dec 22, 2025 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −87 | $2.97 | $258 |
| Dec 22, 2025 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −302 | $2.97 | $897 |
| Sep 30, 2025 | Edward T. Mathers Director | Grant or award | +4,125 | — | — |
| Sep 30, 2025 | Isaac Manke Director | Grant or award | +5,545 | — | — |
| Sep 22, 2025 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −88 | $2.62 | $231 |
| Sep 22, 2025 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −303 | $2.62 | $794 |
| Jun 30, 2025 | Edward T. Mathers Director | Grant or award | +4,694 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.